Comparative Study
doi: 10.1128/AAC.44.8.2211-2213.2000.
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains
Affiliations
- PMID: 10898706
- PMCID: PMC90044
- DOI: 10.1128/AAC.44.8.2211-2213.2000
Item in Clipboard
Comparative Study
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains
Antimicrob Agents Chemother.
2000 Aug.
Abstract
In vitro activities of seven fluoroquinolones against 140 clinical Acinetobacter baumannii isolates representing 138 different strain types were determined. The rank order of activity was clinafloxacin > gatifloxacin > levofloxacin > trovafloxacin > gemifloxacin = moxifloxacin > ciprofloxacin. The 31 outbreak-related A. baumannii strains were significantly more resistant than were 109 sporadic strains.
Similar articles
-
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.J Antimicrob Chemother. 1997 Nov;40(5):639-51. doi: 10.1093/jac/40.5.639. J Antimicrob Chemother. 1997. PMID: 9421311
-
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.Int J Antimicrob Agents. 2000 Nov;16(3):239-43. doi: 10.1016/s0924-8579(00)00222-3. Int J Antimicrob Agents. 2000. PMID: 11091042
-
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. doi: 10.1128/AAC.43.8.2051. Antimicrob Agents Chemother. 1999. PMID: 10428935 Free PMC article.
-
A critical review of the fluoroquinolones: focus on respiratory infections.Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002. Drugs. 2002. PMID: 11790155 Review.
-
Fluoroquinolones.2020 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643179 Free Books & Documents. Review.
Cited by
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Overexpression of Efflux Pumps, Mutations in the Pumps' Regulators, Chromosomal Mutations, and AAC(6')-Ib-cr Are Associated With Fluoroquinolone Resistance in Diverse Sequence Types of Neonatal Septicaemic Acinetobacter baumannii: A 7-Year Single Center Study.Front Microbiol. 2021 Mar 11;12:602724. doi: 10.3389/fmicb.2021.602724. eCollection 2021. Front Microbiol. 2021. PMID: 33776950 Free PMC article.
-
Spatio-Temporal Distribution of Acinetobacter baumannii in Germany-A Comprehensive Systematic Review of Studies on Resistance Development in Humans (2000-2018).Microorganisms. 2020 Mar 6;8(3):375. doi: 10.3390/microorganisms8030375. Microorganisms. 2020. PMID: 32155886 Free PMC article. Review.
-
Acinetobacter baumannii: emergence of a successful pathogen.Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07. Clin Microbiol Rev. 2008. PMID: 18625687 Free PMC article. Review.
-
Treatment options for multidrug-resistant Acinetobacter species.Drugs. 2008;68(2):165-89. doi: 10.2165/00003495-200868020-00003. Drugs. 2008. PMID: 18197724 Review.
References
-
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–651. - PubMed
-
- Bello H, Gonzalez G, Dominguez M, Zemelman R, Garcia A, Mella S. Activity of selected β-lactams, ciprofloxacin, and amikacin against different Acinetobacter baumannii biotypes from Chilean hospitals. Diagn Microbiol Infect Dis. 1997;28:183–186. - PubMed
-
- Blondeau J M. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther. 1999;21:3–40. - PubMed
-
- Bouvet P J, Grimont P A. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol. 1987;138:569–578. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
